Effect of bevacizumab combined with osimertinib on cellular immune function and vascular related growth factors in patients with advanced non-small-cell lung cancer harboring EGFR-T790M mutation
Objective To study clinical efficacy and possible mechanism of bevacizumab combined with osimertinib in the treatment of advanced non-small-cell lung cancer(NSCLC)harboring epidermal growth factor receptor(EGFR)T790M mutation.Methods The clinical data of 88 patients with advanced NSCLC harboring EGFR-T790M mutation from January 2020 to May 2022 were retrospectively analyzed.They were assigned into observation group(n=46)and control group(n= 42)according to different treatment choice.The control group was given osimertinib therapy,the observation group was given bevacizumab combined with osimertinib therapy.The cellular immune function,related vascular growth factors,adverse reactions and short-term efficacy were compared between two groups.Results The remission rate(60.87%vs 38.10%)and the disease control rate(86.96%vs 66.67%)were significantly higher in the observation group than those of the control group(χ2=4.555,5.147,P<0.05).The levels of CD3+,CD4+,CD4+/CD8+ in the observation group were significantly higher than those in the control group,while CD8+ was significantly lower(P<0.05).The levels of serum vascular endothelial growth factor(VEGF),platelet-derived growth factor(PDGF),transforming growth factor β1(TGFβ1)and basic fibroblast growth factor(bFGF)in the observation group were significantly lower than those in the control group(P<0.05).There was no significant difference in digestive tract reaction,liver damage,renal damage,neurotoxicity,thrombocytopenia and leukopenia between groups(P>0.05).Conclusion Bevacizumab combined with osimertinib can improve the therapeutic efficacy of patients with advanced NSCLC harboring EGFR-T790M mutation,which may be related to the improvement of cellular immune function and the inhibition of related vascular growth factors.
万方数据
维普
